Emcure Cuts Semaglutide Drug Price by up to 55% in India

Emcure Announces Major Price Reduction for Weight Management Drug

Emcure Pharmaceuticals has announced a significant price reduction for its weight management drug, Poviztra (semaglutide injection), across India. Effective April 3, 2026, the company will slash the price of the starting dose by 55%, with an average reduction of 47% across all available dosages. This strategic move is aimed at making the scientifically validated obesity treatment more accessible and affordable for a larger patient population in the country.

Detailed Breakdown of the New Pricing

The most substantial price cut applies to the entry-level dose. The 0.25 mg starting dose of Poviztra will now cost ₹3,999 per month, a steep drop from its previous price of ₹8,790. This monthly cost covers four weekly doses administered via a pen device. The price for the highest maintenance dose of 2.4 mg is now set at ₹8,999 for a month's supply. The company stated that the average price cut across all five strengths of the drug is 47%.

Strategic Partnership with Novo Nordisk

Poviztra is the second brand of the innovator molecule semaglutide from the Danish pharmaceutical giant Novo Nordisk. Emcure Pharmaceuticals has an exclusive marketing and distribution agreement with Novo Nordisk to commercialise Poviztra in India. This partnership allows Emcure to leverage its extensive distribution network across the country to bring a globally recognized and clinically proven therapy to the Indian market. While Novo Nordisk manufactures the drug, Emcure is responsible for its distribution and commercialisation, making it the first Indian company to do so for this specific brand.

Addressing India's Growing Obesity Challenge

The decision to lower the price is a direct response to the escalating public health challenge of obesity in India. According to recent data, approximately 254 million people in India live with generalised obesity, and 351 million suffer from abdominal obesity. These conditions are often linked to severe comorbidities such as hypertension, type 2 diabetes, and dyslipidaemia.

Satish Mehta, Chief Executive Officer and Managing Director of Emcure Pharma, stated, “The revised pricing of Poviztra is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base.” The company believes this move will enable more patients to benefit from a proven therapy.

Market Impact and Competitive Landscape

This aggressive pricing strategy positions Emcure to capture a significant share of the rapidly expanding weight management market in India. By making the innovator molecule more affordable, the company challenges existing market dynamics. This move follows a price reduction by Novo Nordisk for its other semaglutide brand, Wegovy, a few months prior. Emcure's decision to further lower the cost through the Poviztra brand is expected to intensify competition and increase patient access.

About Poviztra (Semaglutide)

Poviztra is an injectable prescription medicine administered once a week using a pen device. It is indicated for chronic weight management in adults as an adjunct to a reduced-calorie diet and increased physical activity. The drug is prescribed for individuals with a body mass index (BMI) of 30 kg/m² or higher (obesity), or 27 kg/m² or higher (overweight) in the presence of at least one weight-related comorbidity. The drug is available in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg.

Conclusion

Emcure Pharmaceuticals' decision to drastically cut the price of Poviztra marks a pivotal moment for obesity treatment in India. By making a globally recognized semaglutide injection more affordable, the company is not only positioning itself competitively but also addressing a critical public health need. The new pricing, effective April 3, 2026, is expected to significantly increase the drug's adoption and provide a much-needed therapeutic option for millions of people struggling with obesity and related health conditions.